Evidence map›Paper›PMID 40022133›Full record

ArticleJournal of cardiothoracic surgery2025

Evaluation of hemolysis in patients supported with Impella 5.5: a single center experience.

Jessica S Clothier, Serge Kobsa, Lynette Lester, Nithya Rajeev, Markian Bojko, Jonathan Praeger, Mark Barr, Raymond Lee

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of cardiothoracic surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Jessica S Clothier *Keck School of Medicine, Division of Cardiac Surgery, University of Southern California, 1520 San Pablo St Suite 4300, Los Angeles, CA, 90033, USA.
Serge Kobsa *Keck School of Medicine, Division of Cardiac Surgery, University of Southern California, 1520 San Pablo St Suite 4300, Los Angeles, CA, 90033, USA.
Lynette LesterKeck School of Medicine, Division of Cardiac Surgery, University of Southern California, 1520 San Pablo St Suite 4300, Los Angeles, CA, 90033, USA.
Nithya RajeevKeck School of Medicine, Division of Cardiac Surgery, University of Southern California, 1520 San Pablo St Suite 4300, Los Angeles, CA, 90033, USA.
Markian BojkoKeck School of Medicine, Division of Cardiac Surgery, University of Southern California, 1520 San Pablo St Suite 4300, Los Angeles, CA, 90033, USA.
Jonathan PraegerKeck School of Medicine, Division of Cardiac Surgery, University of Southern California, 1520 San Pablo St Suite 4300, Los Angeles, CA, 90033, USA.
Mark BarrKeck School of Medicine, Division of Cardiac Surgery, University of Southern California, 1520 San Pablo St Suite 4300, Los Angeles, CA, 90033, USA.
Raymond LeeKeck School of Medicine, Division of Cardiac Surgery, University of Southern California, 1520 San Pablo St Suite 4300, Los Angeles, CA, 90033, USA. raymond.lee@med.usc.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHemolysis, variably defined in mechanical circulatory support (MCS), is understudied in percutaneous left ventricular assist devices. We characterize hemolytic sequelae of Impella 5.5-supported patients in the largest series to date.

methodsAll Impella 5.5 patients at our center from 2020 to 2023 were identified (n = 169) and retrospectively reviewed. Patients with a plasma free hemoglobin (PfHb) recorded (and not previously elevated) were included (n = 123). The top (high hemolysis [HH], n = 26) and bottom (low hemolysis [LH], n = 25) quintiles were categorized based on PfHb levels. Analysis between groups identified factors associated with hemolysis.

resultsHH patients had higher admission SCAI stages (p = 0.008), more Impella 5.5 days (23.5 v 10.0, p = 0.001), more additional MCS (16/26 [61.5%] v 6/25 [24.0%], p = 0.015), and more transfusions of packed red blood cells (12.5 v 4.0, p = 0.001), fresh frozen plasma (2.5 v 0.0, p = 0.033), and platelets (3.0 v 0.0, p = 0.002). Logistic regression identified additional MCS (OR 10.82, p = 0.004) and more Impella days (OR 1.13 p = 0.006) as hemolysis risk factors. Eleven (44%) LH and 19/26 (73%) HH patients died, with no significant differences between postoperative complications. Compared with those who died, HH survivors had fewer platelet transfusions (2.0 vs. 5.0, p = 0.01) and less PfHb elevation days (3.0 v 6.0, p = 0.007).

conclusionsHemolysis in this high-risk cohort has a poor prognosis. HH patients spent more days on Impella 5.5, needed more MCS, and required more blood product transfusions.

Indexed as

Heart-Assist DevicesHeart FailureHemolysisAgedFemaleHumansMaleMiddle AgedRetrospective StudiesBlood transfusionsHemolysisImpella 5.5Mechanical circulatory supportPercutaneous LVAD

Identifiers

PMID40022133
PMCPMC11871597

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.